Getinge AB (publ)
Sweden · SE0000202624 · reports in SEK · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +0.6% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 7.7% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 52% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in SEK.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | SEK 28.3B | SEK 31.8B | SEK 34.8B | SEK 35.0B |
| Operating profit | SEK 3.6B | SEK 3.7B | SEK 2.9B | SEK 3.8B |
| Net profit to shareholders | SEK 2.5B | SEK 2.4B | SEK 1.6B | SEK 2.3B |
| Earnings per share | SEK 9.15 | SEK 8.86 | SEK 6.01 | SEK 8.29 |
| Dividend per share | SEK 4.00 | n/a | n/a | SEK 4.60 |
| Cash from operations | SEK 3.4B | SEK 3.0B | SEK 4.6B | SEK 3.9B |
| Cash | SEK 5.7B | SEK 2.7B | SEK 3.0B | SEK 3.4B |
| Total assets | SEK 52.0B | SEK 53.6B | SEK 63.9B | SEK 56.5B |
| Equity | SEK 30.5B | SEK 30.4B | SEK 33.2B | SEK 29.5B |
What they do
In the company's own words, from the annual report.
Getinge är en global leverantör av produkter och tjänster för kirurgi, intensivvård och infektions- bekämpning med verksamhet i 40 länder och egen produktion i 9 länder. Verksamheten bedrivs inom tre affärsområden – Acute Care Therapies, Life Science och Surgical Workflows.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.